New Cousteau-Linked...
Health Care: Drugs
Array BioPharma Inc. (ARRY: NASDAQ)
$3.38 -0.04 | -1.17%
06/04/12 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 3.42 |
| 52 Week High | 4.10 |
| 52 Week Low | 1.58 |
| Avg. Daily Vol. (Mil) | 0.89 |
| Beta (3 year) | 1.64 |
| Share Related Items | |
| Mkt Cap (Mil) | 304.85 |
| Shares Out (Mil) | 89.14 |
| Float (Mil) | 53.30 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 1.30 |
| Current Ratio | 1.40 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | n.a. |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 3.65 |
| Price/Book | 0.00 |
| Price/Cash Flow | -10.10 |
| Per Share Data | |
| Earnings | -0.62 |
| Sales | 0.94 |
| Book Value | 0.00 |
| Cash Flow | -0.34 |
| Business Summary | |
|---|---|
| Array BioPharma, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. | |
| General Information | |
| 3200 Walnut Street
Boulder, CO 80301 |
|
| www.arraybiopharma.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 252 | |
| CEO: Ron Squarer | |
| Short Interest | |
| Current Month (Mil) | 3.24 |
| Previous Month (Mil) | 3.35 |
| Short Interest Ratio (Days) | 4.20 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -31.10 |
| Return on Investments | -307.00 |
| Profitability | |
| Gross Margin | 77.80 |
| EBIT Margin | -29.40 |
| Profit Margin | -44.70 |
Portfolios with ARRY
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- Contributor7 Cancer Drug Stocks to Kno...
- ContributorStocks Under-$10 Moving Hig...
- ContributorUnder-$10 Setting Up To Tra...
- UserASCO 2010
- ContributorBarron's Activist Stocks 1-...
- UserPART 6 JPMorgan 28th Annual...
- ContributorBarron's Activist Stocks 1-...
- ContributorBarron's Activist Stocks 1-...
Latest ARRY Headlines from TheStreet
- ASCO 2012 Live Blog -- Monday 06.04.12 | 06:06 am
- Biotech Stock Mailbag: ASCO, Celldex, Obesity Drug Game-Changer 05.25.12 | 05:05 am
- The Next Big Thing in Biotech: ASCO Conference
05.25.12 | 05:05 am - 7 Stocks Under $10 Making Big Moves 05.17.12 | 12:05 pm
- Biotech Stock Live Chat Recap: ASCO & Obesity 05.17.12 | 11:05 am
- ASCO '12 Abstract Dump: Cancer Stocks in Focus (Update) 05.17.12 | 06:05 am
- ASCO '12 Abstract Dump: Cancer Stocks in Focus 05.16.12 | 06:05 pm
- Hot Biotech Stocks Traded by Hedge Funds in First Quarter 05.16.12 | 07:05 am
- 7 Cancer Drug Stocks to Know Right Now 03.14.12 | 09:03 am
- Array BioPharma Stock Gaps Down On Today's Open (ARRY) 02.09.12 | 08:02 am
Press Releases for ARRY
- Promising Data For KRAS Mutant Advanced NSCLC Patients Presented At ASCO - Business Wire 06.04.12 | 05:06 pm
- MEK162 Shows Promising Clinical Activity In Ongoing Phase 2 Trial - Business Wire 06.04.12 | 04:06 pm
- Array BioPharma To Present At The Jefferies 2012 Global Healthcare Conference - Business Wire 05.30.12 | 03:05 pm
- Array BioPharma And Genentech's Strategic Alliance Voted Breakthrough Alliance Of 2012 - Business Wire 05.14.12 | 06:05 pm
- Liam Ratcliffe, M.D., Ph.D., Independent Director, Array BioPharma Board Of Directors (Photo: Business Wire) - Business Wire 04.30.12 | 08:04 am
- Array BioPharma To Report Financial Results For The Third Quarter Of Fiscal 2012 On April 30, 2012 - Business Wire 04.23.12 | 04:04 pm
- Array BioPharma Names Howard Holden, Ph.D., Vice President Of Regulatory Affairs And Quality Assurance - Business Wire 04.16.12 | 08:04 am
- Encouraging Selumetinib Results Announced For Phase 2 Trial In Ovarian Cancer - Business Wire 04.04.12 | 09:04 am
- Array BioPharma To Present At The Cowen And Company 32nd Annual Health Care Conference - Business Wire 02.27.12 | 01:02 pm
- Array BioPharma Announces Closing Of Public Offering Of Common Stock And Exercise Of Overallotment Option - Business Wire 02.14.12 | 09:02 am
Partner Headlines for ARRY
- Array BioPharma Says Encouraging Selumetinib Results Announced for Phase 2 Trial in Ovarian Cancer - Benzinga 04.04.12 | 09:04 am
- Company News for February 10, 2012 - Corporate Summary - Zacks 02.10.12 | 10:02 am
- Biotech Stocks To Watch In 2012 - Seeking Alpha 02.06.12 | 09:02 am
- Array BioPharma Names Gwen A. Fyfe, M.D. to Board of Directors - Benzinga 01.30.12 | 04:01 pm
- Zacks #1 Rank Additions for Thursday - Tale of the Tape - Zacks 11.03.11 | 09:11 am
- Bottom Bounce for Array BioPharma - Seeking Alpha 06.29.11 | 09:06 am
- Future Biotech Superstars - Seeking Alpha 03.30.11 | 09:03 am
- How Array Got Its Groove Back - SeekingAlpha.com 04.28.10 | 01:04 pm
- Biotech Gets Busy With Small Company Financings - SeekingAlpha.com 04.25.10 | 08:04 am
- Array and Novartis Ink Deal - Analyst Blog - Zacks 04.22.10 | 02:04 pm
